Atara Biotherapeutics (ATRA) Net Income (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Net Income came in at -$4.1 million in Q1 2026, down 110.91% YoY from $38.0 million in Q1 2025, and down 22.34% on a QoQ basis from -$3.4 million in Q4 2025.
Atara Biotherapeutics (ATRA) Net Income (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Net Income data on file, last reported at -$4.1 million in Q1 2026.
- Quarterly Net Income fell 110.91% year-over-year to -$4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.4 million (up 39.59% YoY) and the FY2025 annual result came in at $32.7 million, up 138.3% from the prior year.
- Net Income declined to -$4.1 million in Q1 2026, from -$3.4 million in the prior quarter.
- In the past five years, Net Income ranged from a high of $38.0 million in Q1 2025 to a low of -$88.1 million in Q1 2022.
- A 5-year average of -$33.0 million and a median of -$21.9 million in 2024 frame the typical range for Net Income.
- Annual changes were most pronounced in 2023 — Net Income tumbled 485.08% — and 2025, when it jumped 219.71%.
- Tracing ATRA's Net Income over 5 years: stood at -$74.6 million in 2022, then climbed by 18.94% to -$60.4 million in 2023, then jumped by 79.0% to -$12.7 million in 2024, then jumped by 73.31% to -$3.4 million in 2025, then dropped by 22.34% to -$4.1 million in 2026.
- The last three Net Income figures came in at -$4.1 million (Q1 2026), -$3.4 million (Q4 2025), and -$4.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | 81.49 Mn |
| 10 | Atara Biotherapeutics | 146.12 Mn | 129.57 Mn | 439,000.00 | -4.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.83 Mn |
| Mar 31, 2026 | -4.15 Mn |
| Dec 31, 2025 | -3.39 Mn |
| Sep 30, 2025 | -4.30 Mn |
| Jun 30, 2025 | 2.39 Mn |
| Mar 31, 2025 | 38.01 Mn |
| Dec 31, 2024 | -12.69 Mn |
| Sep 30, 2024 | -21.91 Mn |
| Jun 30, 2024 | -19.05 Mn |
| Mar 31, 2024 | -31.75 Mn |
| Dec 31, 2023 | -60.45 Mn |
| Sep 30, 2023 | -69.80 Mn |
| Jun 30, 2023 | -71.11 Mn |
| Mar 31, 2023 | -74.77 Mn |
| Dec 31, 2022 | -74.57 Mn |
| Sep 30, 2022 | -84.09 Mn |
| Jun 30, 2022 | 18.47 Mn |
| Mar 31, 2022 | -88.11 Mn |
| Dec 31, 2021 | -93.56 Mn |
| Sep 30, 2021 | -84.66 Mn |